237 related articles for article (PubMed ID: 7716719)
1. Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease.
Borst MJ; VanCamp JM; Peacock ML; Decker RA
Surgery; 1995 Apr; 117(4):386-91. PubMed ID: 7716719
[TBL] [Abstract][Full Text] [Related]
2. Occurrence of MEN 2a in familial Hirschsprung's disease: a new indication for genetic testing of the RET proto-oncogene.
Decker RA; Peacock ML
J Pediatr Surg; 1998 Feb; 33(2):207-14. PubMed ID: 9498388
[TBL] [Abstract][Full Text] [Related]
3. RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease.
Pasini B; Rossi R; Ambrosio MR; Zatelli MC; Gullo M; Gobbo M; Collini P; Aiello A; Pansini G; Trasforini G; degli Uberti EC
Surgery; 2002 Apr; 131(4):373-81. PubMed ID: 11935126
[TBL] [Abstract][Full Text] [Related]
4. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
5. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease.
Inoue K; Shimotake T; Inoue K; Tokiwa K; Iwai N
J Pediatr Surg; 1999 Oct; 34(10):1552-4. PubMed ID: 10549772
[TBL] [Abstract][Full Text] [Related]
7. C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease.
Caron P; Attié T; David D; Amiel J; Brousset F; Roger P; Munnich A; Lyonnet S
J Clin Endocrinol Metab; 1996 Jul; 81(7):2731-3. PubMed ID: 8675603
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.
Landsvater RM; Jansen RP; Hofstra RM; Buys CH; Lips CJ; Ploos van Amstel HK
Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249
[TBL] [Abstract][Full Text] [Related]
9. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome).
Oishi S; Sato T; Takiguchi-Shirahama S; Nakamura Y
Endocr J; 1995 Aug; 42(4):527-36. PubMed ID: 8556060
[TBL] [Abstract][Full Text] [Related]
10. Detection of RET mutations in multiple endocrine neoplasia type 2a and familial medullary thyroid carcinoma by denaturing gradient gel electrophoresis.
Peacock ML; Borst MJ; Sweet JD; Decker RA
Hum Mutat; 1996; 7(2):100-4. PubMed ID: 8829625
[TBL] [Abstract][Full Text] [Related]
11. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects.
Beldjord C; Desclaux-Arramond F; Raffin-Sanson M; Corvol JC; De Keyzer Y; Luton JP; Plouin PF; Bertagna X
J Clin Endocrinol Metab; 1995 Jul; 80(7):2063-8. PubMed ID: 7608256
[TBL] [Abstract][Full Text] [Related]
12. Mutations of the RET proto-oncogene in Hirschsprung's disease.
Edery P; Lyonnet S; Mulligan LM; Pelet A; Dow E; Abel L; Holder S; Nihoul-Fékété C; Ponder BA; Munnich A
Nature; 1994 Jan; 367(6461):378-80. PubMed ID: 8114939
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain.
Sánchez B; Robledo M; Biarnes J; Sáez ME; Volpini V; Benítez J; Navarro E; Ruiz A; Antiñolo G; Borrego S
J Med Genet; 1999 Jan; 36(1):68-70. PubMed ID: 9950371
[TBL] [Abstract][Full Text] [Related]
14. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
[TBL] [Abstract][Full Text] [Related]
15. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease.
Romeo G; Ronchetto P; Luo Y; Barone V; Seri M; Ceccherini I; Pasini B; Bocciardi R; Lerone M; Kääriäinen H
Nature; 1994 Jan; 367(6461):377-8. PubMed ID: 8114938
[TBL] [Abstract][Full Text] [Related]
16. RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer.
Blaugrund JE; Johns MM; Eby YJ; Ball DW; Baylin SB; Hruban RH; Sidransky D
Hum Mol Genet; 1994 Oct; 3(10):1895-7. PubMed ID: 7849720
[No Abstract] [Full Text] [Related]
17. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
Sansó G; Domené HM; Iorcansky S; Barontini M
Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
[TBL] [Abstract][Full Text] [Related]
18. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
Frilling A; Dralle H; Eng C; Raue F; Broelsch CE
Surgery; 1995 Dec; 118(6):1099-103; discussion 1103-4. PubMed ID: 7491529
[TBL] [Abstract][Full Text] [Related]
19. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
Eng C; Smith DP; Mulligan LM; Nagai MA; Healey CS; Ponder MA; Gardner E; Scheumann GF; Jackson CE; Tunnacliffe A
Hum Mol Genet; 1994 Feb; 3(2):237-41. PubMed ID: 7911697
[TBL] [Abstract][Full Text] [Related]
20. Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland.
Padberg BC; Schröder S; Jochum W; Kastendieck H; Roth J; Heitz PU; Komminoth P
Am J Pathol; 1995 Dec; 147(6):1600-7. PubMed ID: 7495285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
